MGMT and glioblastoma: Therefore, to facilitate the decision process of “how far can you go” vs “how far must we go”, we analyzed whether a methylated MGMT promoter is able to balance the disadvantage of post-op residual tumor regarding tumor progression, PFS, OS as well as clinical outcome in IDH-wildtype glioblastoma patients.